Results 171 to 180 of about 25,411 (262)

Effects of SGLT2 inhibitors across the spectrum of albuminuria in cardiovascular–kidney–metabolic conditions: A pooled analysis of randomised trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1105-1115, February 2026.
Abstract Background Albuminuria is associated with an increased risk of cardiovascular and kidney events. Sodium glucose co‐transporter 2 inhibitors (SGLT2i) reduce albuminuria and improve kidney outcomes in patients with albuminuric chronic kidney disease (CKD).
João Pedro Ferreira, Pedro Marques, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, Abhinav Sharma, Francisco Vasques‐Nóvoa, Luís Mendonça, João Sérgio Neves, Milton Packer, Faiez Zannad   +10 more
wiley   +1 more source

Nonsteroidal mineralocorticoid receptor antagonists and cardiovascular events in type 2 diabetes: a retrospective study. [PDF]

Eur Heart J Cardiovasc Pharmacother
Chen YH, Fang YW, Chen MT, Liou HH, Tsai MH.   +4 more
europepmc   +1 more source

Efficacy and safety of glucagon‐like peptide 1 receptor agonists across all health outcomes in type 2 diabetes: An umbrella review and evidence map of randomised controlled trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 2, Page 1136-1149, February 2026.
Abstract Aim Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) have been established as effective treatments for type 2 diabetes, offering benefits beyond glycaemic control; however, their associations across multiple health outcomes remain insufficiently assessed.
Dongjin Yeo, Yeona Jo, Jinyoung Jeong, Yi Deun Jeong, Ho Geol Woo, Yejun Son, Sunyoung Kim, Sang Youl Rhee, Dong Keon Yon   +8 more
wiley   +1 more source

Caring for Australians and New Zealanders with kidney Impairment guidelines commentary on the Kidney Disease: Improving Global Outcomes clinical practice guideline for management of diabetes and chronic kidney disease

Internal Medicine Journal, Volume 56, Issue 2, Page 274-279, February 2026.
Abstract Diabetes is a leading cause of kidney failure, and individuals with both diabetes and chronic kidney disease (CKD) experience significantly higher rates of complications and mortality. The international guideline developer Kidney Disease: Improving Global Outcomes (KDIGO) has produced clinical practice guidelines that reflect recent advances ...
Hannah Wallace, Mia E. Abdy, Kathie Anderson, Effie Johns, Thu Nguyen, Carla Scuderi, Vincent Lee, David J. Tunnicliffe, Min Jun, on behalf CARI Guidelines Steering Committee, Emily See, Leanne Brown, Helen Coolican, Jonathan Craig, Vanessa Cullen, Jeffrey Ha, Rathika Krishnasamy, Kelly Lambert, Casey Light, Emmy O'Neill, Hannah Smith, Andrea Viecelli   +21 more
wiley   +1 more source

The biology of PKM2 in the metabolism and senescence in diabetic kidney disease

Journal of Diabetes Investigation, Volume 17, Issue 2, Page 197-204, February 2026.
ABSTRACT Diabetic kidney disease (DKD) is one of the most common causes of chronic kidney disease that leads to end‐stage kidney disease, and its progression is closely linked to metabolic stress within renal tubular cells. Under long‐term hyperglycemia, cells shift their glucose metabolism from normal oxidative phosphorylation toward glycolysis.
Md. Imrul Kayes, Keizo Kanasaki
wiley   +1 more source

Nonsteroidal Versus Steroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Real-World Evidence From a Multicenter Cohort Study. [PDF]

J Am Heart Assoc
Wu JY, Tseng KJ, Lin YM.
europepmc   +1 more source

Emerging methods for subtype differentiation in primary aldosteronism

Journal of Internal Medicine, Volume 299, Issue 2, Page 178-195, February 2026.
Abstract Primary aldosteronism (PA) is a common cause of hypertension. Compared to patients with essential hypertension, untreated PA is associated with a two‐ to fourfold greater risk of cardiovascular disease, renal failure, and death. PA is caused by increased secretion of aldosterone from one adrenal gland in 30% of the patients and both adrenal ...
Oskar Ragnarsson, C. Christofer Juhlin, Tobias Åkerström, Per Dahlqvist, Henrik Falhammar, Per Hellman   +5 more
wiley   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials. [PDF]

BMC Cardiovasc Disord
Wu J, Pei Y, Wu J, Huang Y.
europepmc   +1 more source

Predictors of Atrial High‐Rate Episodes and Inappropriate Device Therapy in Implantable Cardioverter Defibrillators

Pacing and Clinical Electrophysiology, Volume 49, Issue 2, Page 71-81, February 2026.
ABSTRACT Background Implantable cardioverter defibrillator (ICD) therapy can prevent sudden cardiac death, but poses a risk of inappropriate device therapy (IDT), which is linked to worse outcomes and reduced quality of life. On the other hand, ICDs can function as an early warning system for atrial arrhythmias.
Marthe J. Huntelaar, Luuk H. G. A. Hopman, Anne‐Lotte C. J. van der Lingen, Mischa T. Rijnierse, Michiel J. B. Kemme, Cornelis P. Allaart, Vokko P. van Halm   +6 more
wiley   +1 more source

Renin-guided therapy with mineralocorticoid receptor antagonists in primary aldosteronism: feasibility study (RETAME-PA) - a clinical research protocol for a randomised controlled trial. [PDF]

BMJ Open
Merabtine A, Leung AA, Kline GA, Dubrofsky L, Hundemer GL, Goupil R.   +5 more
europepmc   +1 more source